secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2022-02-14T23:59:59+00:00
Accession:  0001493152-22-004309
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics grants 694,424 RSUs tied to Roche collaboration milestones
--------------------------------------------------------------------------------

- RSUs awarded to employees and executive officers; half vest over 4 years, half upon milestone achievement under Roche License Agreement.
- Roche deal includes $50M upfront payment and up to $620M in developmental, regulatory, and commercial milestones.
- OpRegen cell therapy for ocular disorders (dry AMD with geographic atrophy) is subject of the exclusive worldwide license.
- Tiered double-digit royalties on net sales of OpRegen, subject to intellectual property and competitive product offsets.
- RSUs granted under 2021 Equity Incentive Plan; continued vesting requires continuous service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315222004309/0001493152-22-004309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315222004309/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-004309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer